NKTR 223Alternative Names: NKTR-223
Latest Information Update: 19 Nov 2013
At a glance
- Originator Nektar Therapeutics
- Class Peptides; Polymers
- Mechanism of Action Cell membrane permeability modulators; Cell membrane structure modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Gram-negative infections
Most Recent Events
- 19 Nov 2013 Preclinical trials in Gram-negative infections in USA (Parenteral)